BACKGROUND: COPD is a major cause of morbidity and mortality in the United States as
well as throughout the rest of the world. An exacerbation of COPD (periodic escalations of …

Bronchodilators are central in the treatment of of airways disorders. They are the mainstay of
the current management of chronic obstructive pulmonary disease (COPD) and are critical in …

Background We evaluated the effect of dual, longacting inhaled bronchodilator treatment on
exacerbations in patients with severe and very severe chronic obstructive pulmonary …

We investigated the efficacy and safety of dual bronchodilation with QVA149 versus its
monocomponents indacaterol and glycopyrronium, tiotropium and placebo in patients with …

Study objective To examine the efficacy and safety of the once-daily, inhaled, long-acting
muscarinic antagonist/β 2-agonist combination umeclidinium/vilanterol (UMEC/VI) …

Recognizing the clinical heterogeneity of COPD suggests a specific therapeutic approach
directed by the so-called clinical phenotypes of the disease. The Spanish COPD Guidelines …

Background The current Global initiative for chronic Obstructive Lung Disease (GOLD)
treatment strategy recommends the use of one or more bronchodilators according to the …

The recognition that there are some patients with features of asthma and chronic obstructive
pulmonary disease (COPD) has highlighted the need to develop more specific treatments for …

Rationale: Current Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy
recommends the combination of two long-acting bronchodilators of different pharmacologic …

Background Combination long-acting bronchodilator therapy may be more effective than
long-acting bronchodilator monotherapy in COPD. Our objectives were to compare the …